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Interestingly, however, the degree of
branching in glycogen in hearts from
transgenic mice expressing mutant g2
was reported tobe lowerdespite amarked
decrease in AMPK activity (Davies et al.,
2006). Clearly, further studies will be
required to determine the effect of
glycogencontent anddegreeof branching
on AMPK activity in vivo.
In addition to allosteric inhibition,
McBride et al. report that the branched
oligosaccharide inhibited T172 phosphor-
ylation by either LKB1 or CaMKKb but
did not affect dephosphorylation. The
branched oligosaccharide did not directly
inhibit LKB1, implying that inhibition of
T172 phosphorylation is mediated by
binding of the oligosaccharide to AMPK.
It will be important to determine whether
the presence of the GBD is required for
this effect, or whether some other part of
the AMPK molecule is involved. Paradox-
ically, previous work in yeast revealed that
the GBD plays a role in regulating SNF1,
the S. cerevisiae homolog of AMPK, inde-
pendently of glycogen (Momcilovic et al.,
2008). It remains to be determined how
theGBD in SNF1 regulates kinase activity,
for instance whether some other molecule
binds to the domain and whether this
might also be the case with mammalian
AMPK. The new study raises a number
of questions: Does glycogen inhibit
AMPK in vivo and, if so, what is the effect
of glycogen branching on inhibition? Do
other oligosaccharides regulate AMPK?
What is the molecular basis for the allo-
steric inhibition of AMPK and decrease
in T172 phosphorylation by glycogen?
Given the dynamism in the field, it is likely
that we will not have to wait too long for
the answers to emerge.
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The first crystal structure of a full-length nuclear receptor complex on DNA reveals an interdomain contact
between the ligand- and DNA-binding domains of subunits and illuminates the role of the 50 extension of
the binding site in polarity of positioning. These findings have possible functional implications.The recently reported crystal structure of
a full-length nuclear receptor complex on
DNA (Chandra et al., 2008) represents
a long-awaited and significant step for-
ward on the way to understanding struc-
ture-function relationships for this impor-
tant family of transcription regulators.
Nuclear receptors (NR) control multiple
physiological phenomena (i.e., embryo-
genesis, cell growth, and apoptosis). As8 Cell Metabolism 9, January 7, 2009 ª2009activators or suppressors of gene function
they regulateseveral pathways through the
recruitment of cofactor proteins. Nuclear
receptors exhibit a highly conserved
structural organization of four functional
modules, two of which are well character-
ized functionally and structurally. The
central zinc finger DNA-binding domain
(DBD) is the most conserved, while the
C-terminal ligand-binding domain (LBD)Elsevier Inc.that harbors the ligand-dependent activa-
tion function (AF2) is also highly conserved
but to a lesser extent. The other two
domains are variable both in length and
sequence. The hinge region constitutes
a small domain of 30–50 amino acids that
links the DBD and LBD. Finally, there is the
N-terminal AB domain, whose size ranges
from 20 amino acids in Vitamin D Receptor
toover 600 in the steroid ligands subfamily.
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PreviewsThis domain harbors a ligand-
independent function, AF1.
The first crystal structure of
a DBD (that of the glucocorti-
coid receptor) on DNA was
solved in 1991 (Luisi et al.,
1991). It showed the protein
fold as well as details of the
DNA-protein recognition at
atomic resolution. Four years
later, the crystal structure of
an RXR LBD (Bourguet et al.,
1995) revealed the canonical
fold of the domain. Shortly
afterwards, the atomic struc-
tures of the liganded retinoic
acid receptor (RAR) (Renaud
et al., 1995) and thyroid
receptor (TR) (Wagner et al.,
1995) LBDs showed the role
of the ligand in the positioning
of H12, the terminal helix
that harbors the ligand-de-
pendent activation function
(AF2) in an active form. The
high sequence variability of
the remaining domains, in
particular the AB domain,
presented the characteristics
of unfolded proteins and re-
sisted attempts to determine
their structure.
The peroxisome prolifera-
tor-activated receptor (PPAR)
is implicated in metabolic
pathways. The family includes
three members with different
tissue distributions and distinct biological
functions. They form obligate hetero-
dimers with RXRs, which bind to specific
response elements (PPREs) present in
the promoters of their target genes. Most
PPREs are variants of a direct repeat of
the consensus motif AGGTCA separated
by one base pair (DR1) (for a recent review
of PPAR biology, see Bensinger and Ton-
tonoz, 2008).
The crystal structure of PPARg-RXRa
heterodimers on DNA provides the first
near-atomic resolution information on
the quaternary structure (domain distribu-
tion) within the complex. While the data
confirm the previous structural informa-
tion on isolated domains, namely DBDs
bound to DR1 (Rastinejad et al., 2000)
and heterodimers of PPARg-RXR LBDs
(Gampe et al., 2000), two important
features are revealed. One is the impor-
tance of the 50 extension of DR1 in the
positioning of the complex on the target
gene. The interaction of the DNA exten-
sion with the hinge peptide of PPARg
appears to play a major role in the posi-
tioning of the DBD. The second and
most unexpected feature is the interdo-
main contact between the LBD of PPARg
and the DBD of RXRa. A compact PPARg,
with its LBD in a central position of the
complex, nests on an extended RXR
yet remains accessible to a coactivator
partner. The interface involves amino
acids in strandS4 of the b sheet of PPARg,
a feature specific to the PPAR family of
receptors (most NRs have only a two-
strand b sheet). Mutation of a phenylala-
nine in that interface region affects PPRE
binding and transcription activation, sug-
gesting a functional link between the
observed DBD-LBD interaction and DNA
binding, as discussed by the authors.
Additional mutations should be made to
confirm the hypothesis. The
observed protein-protein
contact is most likely to be
specific to DR1; other het-
erodimers with different
response elements are likely
to exhibit different complex
structures. Support for this
notion comes from the crystal
structure of the insect NR
EcR, where ligand-induced
conformationalchangesof the
b sheet region do not affect
transcription activation (Billas
et al., 2003).
A surprising result to
emerge from this study is the
similarity of the crystal struc-
tures observed with three
ligands known to be func-
tionally different (rosiglita-
zone, BVT.13, and GW9662).
BVT.13 is supposed to affect
the dynamics of the b sheet,
while GW9662 is a known
inhibitor. A reasonable expla-
nation for these puzzling
structural similarities could
be found in crystal packing
contacts, as crystallization
results from the ordered
packing of molecules in a
unique conformation that
suits a regular arrangement.
Crystal growth is possible
only when the pool of mole-
cules in solution can provide
material in the proper conformation. This
could be the result of an equilibrium of
conformers. In PPARg complex crystals,
the packing is dominated by DNA
fiber formation and by protein-DNA and
protein-protein contacts involving the co-
activator peptide. Any alteration of the
position of the coactivator peptide or
H12 would inhibit crystal growth. This 14
amino acid coactivator peptide stabilizes
the active agonist-bound conformation
of H12. The peptide and PPAR H12 both
form key packing contacts with DNA
(Figure 1). The dynamic character of the
complexes is shown by the proton
exchange data presented, which support
a pronounced mobility in some parts of
the complex.
What do we learn about the AB domains
and the hinges? For the latter, their
dynamic character is confirmed. The
PPARg hinge is clearly visible in the
Figure 1. Crystal Structure of the PPARg-RXRa Heterodimer
on DNA and a Fragment of Crystallographic Symmetry-Related
Complex
Crystal structure of the PPARg-RXRa heterodimer on DNA (top) and a fragment
of crystallographic symmetry-related complex (bottom). The DBD of PPARg
hidden on the top of the picture can be seen on the symmetry-related complex
(bottom). This figureshowsclearly thecrystallographicpackingcontact between
two complexes mediated by the coactivator (CoA) peptide and H12 of PPARg.
Color code: DNA (purple); coactivator (CoA) peptides (red); PPARg (green);
RXRa (cyan). The PPARg and RXRa helices H12 are represented in orange.
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Previewselectron density map thanks to a packing
contact that stabilizes it, and the hinge
region of RXR lacks secondary structure.
The flexibility of the hinges is adapted to
their linker function that has to accommo-
date several conformations. The AB
domains are not visible in the electron
density map, most likely due to a disor-
dered structure. According to their
sequence these functionally important
domains belong to the family of intrinsically
disordered proteins. In the absence of the
proper functional partner, there is no rele-
vant structural information.
In summary, the present crystal struc-
ture of thePPARg-RXRcomplex is a snap-
shot of a structural state that is specific to
the binding to a DR1 response element. It10 Cell Metabolism 9, January 7, 2009 ª200provides two potentially interesting func-
tional insights that are worth further inves-
tigation. This work highlights the need for
further structural information from other
systems and with different response
elements in order to derive some general
rules.
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